JP2009539848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539848A5 JP2009539848A5 JP2009514375A JP2009514375A JP2009539848A5 JP 2009539848 A5 JP2009539848 A5 JP 2009539848A5 JP 2009514375 A JP2009514375 A JP 2009514375A JP 2009514375 A JP2009514375 A JP 2009514375A JP 2009539848 A5 JP2009539848 A5 JP 2009539848A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- alkyl
- membered
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 20
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 18
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 15
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- 150000001602 bicycloalkyls Chemical group 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- -1 2-((pyridin-3-yloxy) methyl) piperazine-1- yl Chemical group 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81127506P | 2006-06-06 | 2006-06-06 | |
| US60/811,275 | 2006-06-06 | ||
| US85283606P | 2006-10-19 | 2006-10-19 | |
| US60/852,836 | 2006-10-19 | ||
| US90124007P | 2007-02-13 | 2007-02-13 | |
| US60/901,240 | 2007-02-13 | ||
| PCT/US2007/013425 WO2007146066A2 (en) | 2006-06-06 | 2007-06-06 | Novel piperazines, pharmaceutical compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013125127A Division JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539848A JP2009539848A (ja) | 2009-11-19 |
| JP2009539848A5 true JP2009539848A5 (enExample) | 2010-07-22 |
| JP5363315B2 JP5363315B2 (ja) | 2013-12-11 |
Family
ID=38658579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514375A Expired - Fee Related JP5363315B2 (ja) | 2006-06-06 | 2007-06-06 | 新規ピペラジン、医薬組成物、およびその使用方法 |
| JP2013125127A Pending JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013125127A Pending JP2013199489A (ja) | 2006-06-06 | 2013-06-14 | 新規ピペラジン、医薬組成物、およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2044038B1 (enExample) |
| JP (2) | JP5363315B2 (enExample) |
| CA (1) | CA2659512C (enExample) |
| ES (1) | ES2498043T3 (enExample) |
| WO (1) | WO2007146066A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2498043T3 (es) * | 2006-06-06 | 2014-09-24 | Cornerstone Therapeutics Inc. | Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas |
| SI2206707T1 (sl) | 2007-10-24 | 2014-11-28 | Astellas Pharma Inc. | Azolkarboksamidna spojina ali njena sol |
| PT2268646E (pt) | 2008-04-11 | 2013-12-10 | Janssen Pharmaceutica Nv | Aminas de tiazolopiridina-2-iloxi-fenil e de tiazolopirazina-2-iloxi-fenilo como moduladores da hidrolase de leucotrieno a4 |
| WO2010044441A1 (ja) | 2008-10-17 | 2010-04-22 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
| KR101051077B1 (ko) * | 2008-12-05 | 2011-07-21 | 한국화학연구원 | 2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제 |
| MX2011012190A (es) | 2009-05-14 | 2011-12-08 | Janssen Pharmaceutica Nv | Compuestos con dos porciones de heteroarilo biciclico fusionado como moduladores de la leucotrieno a4 hidrolasa. |
| KR20120081119A (ko) * | 2009-09-04 | 2012-07-18 | 잘리커스 파마슈티컬즈 리미티드 | 통증 및 간질 치료를 위한 치환된 헤테로고리 유도체 |
| TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α７活化劑之用途 |
| WO2011152442A1 (ja) * | 2010-06-03 | 2011-12-08 | 塩野義製薬株式会社 | 2－クロロ－6－フルオロベンゾオキサゾールの製造方法 |
| BR112013028895A2 (pt) | 2011-05-10 | 2016-08-09 | Bayer Ip Gmbh | (tio)carbonilamidinas bicíclicas |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| WO2014134306A1 (en) | 2013-03-01 | 2014-09-04 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| US9890142B2 (en) | 2013-07-10 | 2018-02-13 | Meiji Seika Pharma Co., Ltd. | PDE4 inhibitor |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| FR3022784B1 (fr) * | 2014-06-26 | 2017-09-08 | Ecole Normale Superieure Lyon | Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes |
| CN112920137A (zh) * | 2021-03-02 | 2021-06-08 | 南京波普生物医药研发有限公司 | 噻唑医药中间体合成工艺 |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2165176A1 (en) * | 1993-06-18 | 1995-01-05 | Samuel L. Graham | Inhibitors of farnesyl-protein transferase |
| EP0820452B1 (en) * | 1995-04-07 | 2003-06-04 | Schering Corporation | Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
| US5929077A (en) * | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
| US6372747B1 (en) * | 1998-12-18 | 2002-04-16 | Schering Corporation | Farnesyl protein transferase inhibitors |
| US6878700B1 (en) * | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| WO2003016274A2 (en) * | 2001-08-21 | 2003-02-27 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| WO2004071390A2 (en) * | 2003-02-14 | 2004-08-26 | Applied Research Systems Ars Holding N.V. | Piperazine-2-carboxamide derivatives |
| US8188277B2 (en) * | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| ES2498043T3 (es) * | 2006-06-06 | 2014-09-24 | Cornerstone Therapeutics Inc. | Piperazinas novedosas, composiciones farmacéuticas y métodos de uso de las mismas |
-
2007
- 2007-06-06 ES ES07809388.7T patent/ES2498043T3/es active Active
- 2007-06-06 EP EP07809388.7A patent/EP2044038B1/en not_active Not-in-force
- 2007-06-06 CA CA2659512A patent/CA2659512C/en not_active Expired - Fee Related
- 2007-06-06 JP JP2009514375A patent/JP5363315B2/ja not_active Expired - Fee Related
- 2007-06-06 WO PCT/US2007/013425 patent/WO2007146066A2/en not_active Ceased
-
2013
- 2013-06-14 JP JP2013125127A patent/JP2013199489A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515852A5 (enExample) | ||
| WO2008096870A1 (ja) | アザ架橋環化合物 | |
| JP2014507455A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2014503574A5 (enExample) | ||
| JP2006525359A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| EA201001127A1 (ru) | Производные пиридина | |
| JP2011513305A5 (enExample) | ||
| JP2010535722A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2009530283A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| WO2007087427A3 (en) | Thiazole and thiadiazole compounds for inflammation and immune-related uses | |
| WO2008096231A8 (en) | Antiparasitic agents | |
| JP2009532417A5 (enExample) | ||
| JP2011510068A5 (enExample) | ||
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| JP2015535847A5 (enExample) | ||
| WO2009017098A1 (ja) | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体 |